Am J Clin Exp Immunol

1. WANG W, Shen J, Song D, Fu K, et al
   Identification of macrophage-related genes in bladder cancer patients using single-cell sequencing and construction of a prognostic model.
   Am J Clin Exp Immunol. 2024;13:88-104.
   

   >> Share

   
   

   
   Anal Biochem

2. JIANG Z, Liu Z
   Target recycle initiated entropy driven assembly strategy for sensitive, enzyme-free, and portable miRNA detection.
   Anal Biochem. 2024;693:115593.
   

   >> Share

   
   

   
   Anal Chim Acta

3. ZHANG S, Han Z, Qi H, Zhang Z, et al
   Machine learning assisted microfluidics dual fluorescence flow cytometry for detecting bladder tumor cells based on morphological characteristic parameters.
   Anal Chim Acta. 2024;1317:342899.
   

   >> Share

   
   

   
   Ann Surg Oncol

4. SAM OZDEMIR M, Azamat S, Ozdemir H, Keskin ET, et al
   Preoperative Prediction of Muscle Invasiveness in Bladder Cancer: The Role of 3D Volumetric Radiomics Using Diffusion-Weighted MRI, the VI-RADS Score, or a Combination of Both.
   Ann Surg Oncol. 2024 Jul 13. doi: 10.1245/s10434-024-15760.
   

   >> Share

   
   

   
   BJU Int

5. MATSUDA A, Taoka R, Miki J, Saito R, et al
   Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
   BJU Int. 2024;134:207-218.
   

   >> Share

   
   
6. HOLMBERG L, Skogmar S, Garmo H, Hagberg O, et al
   Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.
   BJU Int. 2024;134:229-238.
   

   >> Share

   
   
7. REMMELINK MJ, Rip Y, Nieuwenhuijzen JA, Ket JCF, et al
   Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review.
   BJU Int. 2024 Jul 17. doi: 10.1111/bju.16471.
   

   >> Share

   
   

   
   BJUI Compass

8. KLEMPFNER H, Anderson P
   Comparison of staging MRI to re-resection for localised bladder cancer: Narrative review.
   BJUI Compass. 2024;5:651-661.
   

   >> Share

   
   

   
   BMC Cancer

9. MOHAMED AH, Mohamed KA, Kayacan E, Nur Y, et al
   Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia.
   BMC Cancer. 2024;24:839.
   

   >> Share

   
   

   
   BMC Urol

10. FU D, Shi X, Yi X, Wu D, et al
    m6A reader IGF2BP2 promotes M2 macrophage polarization and malignant biological behavior of bladder cancer by stabilizing NRP1 mRNA expression.
    BMC Urol. 2024;24:147.
    

    >> Share

    
    
11. ANDERSSON E, Bradvik G, Nilsson FOL, Arpegard J, et al
    Prevalence of diabetes and hospitalization due to poor glycemic control in people with bladder cancer or renal cell carcinoma in Sweden.
    BMC Urol. 2024;24:148.
    

    >> Share

    
    

    
    Cancer Cytopathol

12. LIU TJ, Yang WC, Huang SM, Yang WL, et al
    Evaluating artificial intelligence-enhanced digital urine cytology for bladder cancer diagnosis.
    Cancer Cytopathol. 2024 Jul 14. doi: 10.1002/cncy.22884.
    

    >> Share

    
    

    
    Cancer Lett

13. LI W, Liu J, Yu T, Lu F, et al
    ZDHHC9-mediated Bip/GRP78 S-palmitoylation inhibits unfolded protein response and promotes bladder cancer progression.
    Cancer Lett. 2024;598:217118.
    

    >> Share

    
    

    
    Cancer Res Treat

14. LEE JH, Lee CU, Chung JH, Song W, et al
    Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma.
    Cancer Res Treat. 2024;56:877-884.
    

    >> Share

    
    
15. CHO SW, Lim SH, Kwon GY, Kim CK, et al
    Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
    Cancer Res Treat. 2024;56:893-897.
    

    >> Share

    
    

    
    Cancer Sci

16. AKMAN B, Bursali A, Gurses M, Suner A, et al
    Nucleocytoplasmic beta-catenin expression contributes to neuroendocrine differentiation in muscle invasive bladder cancer.
    Cancer Sci. 2024 Jul 14. doi: 10.1111/cas.16275.
    

    >> Share

    
    

    
    Cancers (Basel)

17. ANGELIS M, Siech C, Di Bello F, Penaranda NR, et al
    Incidence, Characteristics and Survival Rates of Bladder Cancer after Rectosigmoid Cancer Radiation.
    Cancers (Basel). 2024;16:2404.
    

    >> Share

    
    
18. SRINIVASALU VK, Robbrecht D
    Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions.
    Cancers (Basel). 2024;16:2398.
    

    >> Share

    
    
19. DENG Y, Tsai CW, Chang WS, Xu Y, et al
    The Significant Associations between Epigenetic Clocks and Bladder Cancer Risks.
    Cancers (Basel). 2024;16:2357.
    

    >> Share

    
    
20. GUMUS KZ, Nicolas J, Gopireddy DR, Dolz J, et al
    Deep Learning Algorithms for Bladder Cancer Segmentation on Multi-Parametric MRI.
    Cancers (Basel). 2024;16:2348.
    

    >> Share

    
    
21. KURABAYASHI A, Fukuhara H, Furihata K, Iwashita W, et al
    Photodynamic Diagnosis and Therapy in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:2299.
    

    >> Share

    
    

    
    Case Rep Dermatol

22. MIZUTANI Y, Noda E, Kondo M, Hayashi A, et al
    Pityriasis Lichenoides et Varioliformis Acuta Developing during Pembrolizumab Treatment for Bladder Cancer.
    Case Rep Dermatol. 2024;16:116-122.
    

    >> Share

    
    

    
    Cell Biochem Biophys

23. HU L, Wu N, Wang J, Yao M, et al
    Network Pharmacology Combined with Bioinformatics Analysis to Texplore the Potential Mechanism of Phellodendri Chinensis Cortex Against Bladder Cancer.
    Cell Biochem Biophys. 2024 Jul 18. doi: 10.1007/s12013-024-01414.
    

    >> Share

    
    

    
    Cell Signal

24. CHENG C, Zhang Z, Wang J, Wang C, et al
    CircPGM5 regulates Foxo3a phosphorylation via MiR-21-5p/MAPK10 axis to inhibit bladder cancer progression.
    Cell Signal. 2024 Jul 12:111297. doi: 10.1016/j.cellsig.2024.111297.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

25. SALARI A, Ghahari M, Bitaraf M, Fard ES, et al
    Prognostic Value of NLR, PLR, SII, and dNLR in Urothelial Bladder Cancer Following Radical Cystectomy.
    Clin Genitourin Cancer. 2024;22:102144.
    

    >> Share

    
    
26. SKELTON WP 4TH, Masur J, Thomas J, Fallah P, et al
    Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2024;22:102143.
    

    >> Share

    
    

    
    Discov Oncol

27. BOGALE DE
    The roles of FGFR3 and c-MYC in urothelial bladder cancer.
    Discov Oncol. 2024;15:295.
    

    >> Share

    
    

    
    Ecancermedicalscience

28. SARWAR KA, Hussain S, Mahmood A, Alvi ZA, et al
    Comparative efficacy of palliative radiotherapy dose schedules in advanced bladder cancer-associated gross hematuria.
    Ecancermedicalscience. 2024;18:1718.
    

    >> Share

    
    

    
    Eur J Cancer

29. HONG H, Qu Y
    Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
    Eur J Cancer. 2024;207:114173.
    

    >> Share

    
    

    
    Eur J Dermatol

30. ICKRATH K, Fleissner J, Egenolf T, Schmieder A, et al
    Acrodermatitis continua of Hallopeau upon PD-L1 therapy for metastatic urothelial carcinoma.
    Eur J Dermatol. 2024;34:296-298.
    

    >> Share

    
    

    
    Eur Urol

31. PLIMACK ER, Tangen C, Plets M, Kokate R, et al
    Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.
    Eur Urol. 2024 Jul 12:S0302-2838(24)02453-9. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    Eur Urol Focus

32. KLUMPER N, Eckstein M
    Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
    Eur Urol Focus. 2024;10:224-226.
    

    >> Share

    
    
33. BROWN JR, Koshkin VS
    Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Eur Urol Focus. 2024;10:231-233.
    

    >> Share

    
    
34. NALLY E, Young M, Wells C, Fairhead R, et al
    Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
    Eur Urol Focus. 2024;10:219-221.
    

    >> Share

    
    

    
    Eur Urol Oncol

35. SFAKIANOS JP, Basu A, Laliotis G, Cumarasamy S, et al
    Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.
    Eur Urol Oncol. 2024 Jul 15:S2588-9311(24)00174.
    

    >> Share

    
    
36. D'ANDREA D, Soria F, Hurle R, Enikeev D, et al
    Reply to Riccardo Lombardo, Sara Riolo, and Cosimo De Nunzio's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-lab
    Eur Urol Oncol. 2024;7:967-968.
    

    >> Share

    
    
37. LOMBARDO R, Riolo S, De Nunzio C
    Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. 2023;6:508-515.
    Eur Urol Oncol. 2024;7:965-966.
    

    >> Share

    
    
38. MSAOUEL P, Sweis RF, Bupathi M, Heath E, et al
    A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol Oncol. 2024;7:933-943.
    

    >> Share

    
    

    
    Eur Urol Open Sci

39. DE JONG FC, Zuiverloon TCM, Boormans JL
    Reply to Chao Song's Letter to the Editor re: Florus C. de Jong, Iris G. Ifle, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131-9.
    Eur Urol Open Sci. 2024;66:9.
    

    >> Share

    
    
40. SONG C, Bao J, Wan Y, Tang J, et al
    Re: Florus C. de Jong, Iris G. Ifle, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131-9.
    Eur Urol Open Sci. 2024;66:10-11.
    

    >> Share

    
    

    
    Front Oncol

41. NGUYEN NP, Karlsson UL, Page BR, Chirila ME, et al
    Immunotherapy and radiotherapy for older patients with invasive bladder cancer unfit for surgery or chemotherapy: practical proposal by the international geriatric radiotherapy group.
    Front Oncol. 2024;14:1371752.
    

    >> Share

    
    

    
    Heliyon

42. GAO M, Guo H, Xu H, Jin X, et al
    Analysis of cell death-related genes to evaluate the prognostic and immunotherapeutic value in bladder cancer.
    Heliyon. 2024;10:e33200.
    

    >> Share

    
    

    
    Hum Vaccin Immunother

43. ZHAO Z, Jiang Y, Xu K, Xu X, et al
    Response to article by Ruochen Bao et al., "Bibliometric analysis of immunotherapy for bladder cancer: A correspondence".
    Hum Vaccin Immunother. 2024;20:2351617.
    

    >> Share

    
    

    
    Int J Epidemiol

44. KAYYAL-TARABEIA I, Zick A, Kloog I, Levy I, et al
    Beyond lung cancer: air pollution and bladder, breast and prostate cancer incidence.
    Int J Epidemiol. 2024;53:dyae093.
    

    >> Share

    
    

    
    Int J Mol Sci

45. KNEZOVIC D, Milic Roje B, Vilovic K, Frankovic L, et al
    MyD88 Signaling Accompanied by Microbiota Changes Supports Urinary Bladder Carcinogenesis.
    Int J Mol Sci. 2024;25:7176.
    

    >> Share

    
    

    
    Int J Surg

46. CHEN C, Wang C, Huang H, Li H, et al
    The role of adjuvant chemotherapy after radical surgery in patients with lymph node-positive bladder cancer or locally advanced (pT3, pT4a) bladder cancer: A meta-analysis and systematic review.
    Int J Surg. 2024 Jul 17. doi: 10.1097/JS9.0000000000001954.
    

    >> Share

    
    

    
    Int J Urol

47. KIKUCHI E, Hayakawa N
    Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15541.
    

    >> Share

    
    
48. URABE F, Suzuki H, Iwatani K, Kimura T, et al
    Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15537.
    

    >> Share

    
    

    
    J Cancer Res Ther

49. SAH A, Triveni GS, Chandrashekhara SH
    Case series of urachal adenocarcinoma: Imaging features.
    J Cancer Res Ther. 2024;20:1057-1060.
    

    >> Share

    
    

    
    J Clin Med

50. CHIUJDEA S, Ferro M, Vartolomei MD, Lucarelli G, et al
    Epirubicin and Non-Muscle Invasive Bladder Cancer Treatment: A Systematic Review.
    J Clin Med. 2024;13:3789.
    

    >> Share

    
    

    
    J Med Econ

51. TKACZ J, Ireland A, Agatep B, Ellis L, et al
    An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study.
    J Med Econ. 2024 Jul 19:1-14. doi: 10.1080/13696998.2024.2382639.
    

    >> Share

    
    

    
    J Robot Surg

52. TILLU N, Zaytoun O, Kolanukuduru K, Venkatesh A, et al
    Analysis of early perioperative outcomes of robot-assisted radical cystectomy and colonic diversion.
    J Robot Surg. 2024;18:286.
    

    >> Share

    
    

    
    J Zhejiang Univ Sci B

53. ZENG S, Xing S, Zhang Y, Wang H, et al
    Nano-Bacillus Calmette-Guerin immunotherapies for improved bladder cancer treatment.
    J Zhejiang Univ Sci B. 2024;25:557-567.
    

    >> Share

    
    

    
    JAMA Netw Open

54. HAGE CHEHADE C, Jo Y, Gebrael G, Tripathi N, et al
    Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers.
    JAMA Netw Open. 2024;7:e2423186.
    

    >> Share

    
    

    
    Medicine (Baltimore)

55. LAI F, He L, Lia T, Yang Z, et al
    Identification and validation of basement membrane-related genes predicting prognosis and immune infiltration associated with bladder cancer.
    Medicine (Baltimore). 2024;103:e38858.
    

    >> Share

    
    
56. HUANG F, Zhou L, Sun J, Ma X, et al
    Prognostic analysis of anoikis-related genes in bladder cancer: An observational study.
    Medicine (Baltimore). 2024;103:e38999.
    

    >> Share

    
    

    
    Mol Biol Rep

57. MUKHLIF RT, Abol-Enein H, Elsaid AM, Abdelkhalek M, et al
    Association of interleukin6 rs1800796 gene polymorphism and serum level with bladder cancer in Egyptian population.
    Mol Biol Rep. 2024;51:815.
    

    >> Share

    
    

    
    Pharmacol Res

58. TUO Z, Zhang Y, Li D, Wang Y, et al
    Relationship Between Clonal Evolution and Drug Resistance in Bladder Cancer: A Genomic Research Review.
    Pharmacol Res. 2024 Jul 12:107302. doi: 10.1016/j.phrs.2024.107302.
    

    >> Share

    
    

    
    Physiol Genomics

59. LI Q, Sun Y, Zhai K, Geng B, et al
    Microbiota-induced inflammatory responses in bladder tumors promote epithelial-mesenchymal transition and enhanced immune infiltration.
    Physiol Genomics. 2024;56:544-554.
    

    >> Share

    
    

    
    Radiat Oncol

60. GUEL DNB, Laverick N, MacLaren L, MacLeod N, et al
    Adaptive radiotherapy for muscle invasive bladder cancer: a retrospective audit of two bladder filling protocols.
    Radiat Oncol. 2024;19:92.
    

    >> Share

    
    

    
    Tissue Cell

61. ZHANG P, Wang P, Wang Y
    ASF1B is an essential prognostic indicator linked to the growth and resistance characteristics of bladder cancer.
    Tissue Cell. 2024;89:102477.
    

    >> Share

    
    

    
    Virchows Arch

62. LANGE F, Geppert CI, Bahlinger V, Bertz S, et al
    Digital volumetric assessment of CIS and tumor mass compliments conventional histopathological assessment in muscle-invasive urothelial bladder cancer.
    Virchows Arch. 2024 Jul 19. doi: 10.1007/s00428-024-03875.
    

    >> Share

    
    

    
    World J Urol

63. SAYYID RK, Bernardino R, Chavarriaga J, Kumar R, et al
    Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis.
    World J Urol. 2024;42:418.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share